Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Arcus Biosciences (RCUS - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Arcus Biosciences is one of 892 individual stocks in the Medical sector. Collectively, these companies sit at #1 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. RCUS is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for RCUS's full-year earnings has moved 0.42% higher within the past quarter. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the most recent data, RCUS has returned 167.33% so far this year. In comparison, Medical companies have returned an average of -4.84%. As we can see, Arcus Biosciences is performing better than its sector in the calendar year.
Looking more specifically, RCUS belongs to the Medical - Biomedical and Genetics industry, which includes 382 individual stocks and currently sits at #10 in the Zacks Industry Rank. Stocks in this group have gained about 1.91% so far this year, so RCUS is performing better this group in terms of year-to-date returns.
Investors with an interest in Medical stocks should continue to track RCUS. The stock will be looking to continue its solid performance.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Arcus Biosciences (RCUS - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Arcus Biosciences is one of 892 individual stocks in the Medical sector. Collectively, these companies sit at #1 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. RCUS is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for RCUS's full-year earnings has moved 0.42% higher within the past quarter. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the most recent data, RCUS has returned 167.33% so far this year. In comparison, Medical companies have returned an average of -4.84%. As we can see, Arcus Biosciences is performing better than its sector in the calendar year.
Looking more specifically, RCUS belongs to the Medical - Biomedical and Genetics industry, which includes 382 individual stocks and currently sits at #10 in the Zacks Industry Rank. Stocks in this group have gained about 1.91% so far this year, so RCUS is performing better this group in terms of year-to-date returns.
Investors with an interest in Medical stocks should continue to track RCUS. The stock will be looking to continue its solid performance.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on RCUS - FREE